ATE442361T1 - Verfahren zur herstellung kristalliner formen von orlistat - Google Patents

Verfahren zur herstellung kristalliner formen von orlistat

Info

Publication number
ATE442361T1
ATE442361T1 AT04769349T AT04769349T ATE442361T1 AT E442361 T1 ATE442361 T1 AT E442361T1 AT 04769349 T AT04769349 T AT 04769349T AT 04769349 T AT04769349 T AT 04769349T AT E442361 T1 ATE442361 T1 AT E442361T1
Authority
AT
Austria
Prior art keywords
orlistat
crystalline forms
producing crystalline
relates
processes
Prior art date
Application number
AT04769349T
Other languages
English (en)
Inventor
Yatendra Kumar
Mohan Prasad
Keshav Deo
Anand Pandey
Killol Patel
Seema Kanwar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE442361T1 publication Critical patent/ATE442361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04769349T 2003-09-12 2004-09-13 Verfahren zur herstellung kristalliner formen von orlistat ATE442361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1144DE2003 2003-09-12
PCT/IB2004/002957 WO2005026140A1 (en) 2003-09-12 2004-09-13 Process for the preparation of crystalline forms of orlistat

Publications (1)

Publication Number Publication Date
ATE442361T1 true ATE442361T1 (de) 2009-09-15

Family

ID=34308043

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04769349T ATE442361T1 (de) 2003-09-12 2004-09-13 Verfahren zur herstellung kristalliner formen von orlistat

Country Status (6)

Country Link
EP (1) EP1673359B1 (de)
AT (1) ATE442361T1 (de)
DE (1) DE602004023102D1 (de)
ES (1) ES2329474T3 (de)
PT (1) PT1673359E (de)
WO (1) WO2005026140A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1763021B (zh) * 2005-09-29 2010-08-11 杭州华东医药集团生物工程研究所有限公司 一种提纯奥利司他的方法
EP1803714A1 (de) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung kristalliner Formen von Orlistat
EP1944025A1 (de) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stabile pharmazeutische Zusammensetzungen mit Orlistat
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
EP2141236A1 (de) 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Verfahren zur Herstellung von Lipstatin und Mikroorganismen dafür
WO2010042499A1 (en) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
EP2389370A4 (de) * 2009-01-22 2012-09-05 Biocon Ltd Kristalline form von orlistat und verfahren dafür
EP2413911B1 (de) 2009-03-31 2014-02-19 KRKA, D.D., Novo Mesto Progressive emulsionskristallisation
CN102993135B (zh) * 2012-12-31 2015-09-09 山东新时代药业有限公司 一种奥利司他的纯化方法
CN107266395A (zh) * 2017-08-08 2017-10-20 中山万远新药研发有限公司 一种奥利司他ⅰ晶型的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228118T1 (de) * 1999-01-29 2002-12-15 Hoffmann La Roche Reinigung von lipstatin
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
AU2002362061A1 (en) * 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms

Also Published As

Publication number Publication date
PT1673359E (pt) 2009-10-06
EP1673359A1 (de) 2006-06-28
ES2329474T3 (es) 2009-11-26
WO2005026140A1 (en) 2005-03-24
EP1673359B1 (de) 2009-09-09
DE602004023102D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
ATE311386T1 (de) Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
ATE481096T1 (de) Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
ATE478084T1 (de) Verfahren zur herstellung von 4'- azidocytidinderivaten
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
DE69835230D1 (de) Verfahren zur herstellung von nordamerikanischen ginseng fraktionen, enthaltende produkte, und verwendung als immunmodulatoren
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
WO2004029045A3 (en) Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
DE60229267D1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
ATE442361T1 (de) Verfahren zur herstellung kristalliner formen von orlistat
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
WO2004073375A8 (en) Podophyllotoxin derivatives as antitumor agents
DE502004009152D1 (de) Verfahren zur herstellung von derivaten des 4a,5,9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE497958T1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften
ATE451367T1 (de) Verfahren zur herstellung von ziprasidon
ATE497498T1 (de) Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties